News

ASCO’s CancerLinQ and HealthVerity collaborate to accelerate cancer research by linking real-world datasets

ASCO’s CancerLinQ and HealthVerity collaborate to accelerate cancer research by linking real-world datasets 150 150 Doug DeMarra

ASCO’s CancerLinQ and HealthVerity collaborate to accelerate cancer research by linking real-world datasets

JUNE 08, 2022 — 08:30 AM EDT

The collaboration aims to fulfill a shared vision of improving cancer care and research by connecting disparate real-world data to generate deeper insights into unique cancer journeys.

ALEXANDRIA, VA — (ASCO) — CancerLinQ® LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology, and HealthVerity, Inc., today announced a collaboration that will create the nation’s premier real-world oncology data ecosystem to advance cancer care and research for government and public health agencies. The collaboration leverages HealthVerity’s Privacy-Preserving Record Linkage (PPRL) technology to make CancerLinQ oncology data fully interoperable with de-identified patient data from the nation’s largest ecosystem of healthcare and consumer data providers. Qualified researchers will now have the ability to explore longitudinal patient journeys across a multitude of data types that better reveal the context around the origin, progression, treatment, and outcomes for a full breadth of cancer diagnoses.

With only 5 percent of patients with cancer participating in clinical trials, the use of real-world oncology data in research can help expand the pool of knowledge from which researchers can learn. CancerLinQ and HealthVerity allow researchers to learn from all patients with cancer – not only those enrolled in clinical trials–by providing access to broadscale, patient-longitudinal, real-world data that can provide researchers with a more comprehensive view of unique patient journeys.

“CancerLinQ is driven by its goal of improving the care of every single patient with cancer,” said Sean Khozin, MD, MPH, chief executive officer (CEO) of CancerLinQ. “To that end, this new collaboration helps us bring together disparate data-sets that capture the longitudinal experience of patients with cancer, giving us the ability to unlock insights that inform high-quality, equitable patient care and research.”

“We are thrilled to be working alongside CancerLinQ to offer researchers a more comprehensive way to study the complex journeys of cancer patients,” said Andrew Kress, CEO of HealthVerity. “By leveraging the HealthVerity IPGE platform to connect real-world datasets in a HIPAA-compliant and privacy protected manner, we are creating an incredible opportunity for public health and government agencies to make the discoveries that could one day lead to cures for most forms of cancer.”

CancerLinQ has one of the largest and most-diverse real-world-oncology databases that include de-identified data from more than six million patients with cancer and benign hematological conditions from all 50 states. The CancerLinQ network is a growing ecosystem of over 100 cancer centers and community oncology practices.

The HealthVerity IPGE platform is an integrated technology and real-world data infrastructure platform based on four foundational elements—identity, privacy, governance, and exchange—which allow disparate data to be accurately resolved to unique privacy-protected identities, linked, and exchanged for a myriad of use cases.

To learn more about the collaboration and how you can access one of the nation’s largest interoperable de-identified real-world oncology data ecosystem, visit CancerLinQ.org.

View the full release here: https://www.asco.org/about-asco/press-center/news-releases/cancerlinq-and-healthverity-collaborate-linking-datasets

About ASCO

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, Instagram, and YouTube.

About CancerLinQ

CancerLinQ® is a real-world oncology data platform developed by ASCO that collects and aggregates longitudinal EHR data from oncology practices throughout the United States. CancerLinQ improves the quality of patient care and accelerates discovery by securely compiling, harmonizing, analyzing, and de-identifying vast amounts of information on patient characteristics (e.g., molecular profiles, comorbidities), treatments, and long-term side effects. By using data from over six million patients in near real time, CancerLinQ can identify trends and associations between myriad variables, thereby enabling physicians to generate new hypotheses and apply those conclusions to improve care in real-world settings. To learn more about collaborations, visit Collaborations | ASCO CancerLinQ.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Request Demo or More Information

It’s time to Synchronize the Science

Complete the form to explore how synchronizing transformational technologies with the nation’s largest real-world data ecosystem can fundamentally advance the science.

Ipsos MMA and HealthVerity partner to reinvent omnichannel patient and HCP attribution in the pharma industry

Ipsos MMA and HealthVerity partner to reinvent omnichannel patient and HCP attribution in the pharma industry 150 150 Doug DeMarra

Ipsos MMA and HealthVerity partner to reinvent omnichannel patient and HCP attribution in the pharma industry

APRIL 27, 2022 — 08:30 AM EDT

Ipsos MMA brings a new approach to measuring the impact of commercial investments across the patient and physician journey to maximize the value of campaigns for Pharma brands and their agency partners.

NEW YORK, NY — (PRNewswire) — Ipsos MMA, a leader in helping pharma and healthcare brands measure and optimize the value of their patient and HCP promotions, today announced a partnership that integrates Ipsos MMA’s Unified Patient & HCP Attribution model with HealthVerity IPGE, the industry’s leading infrastructure for patient identity resolution, privacy, governance and exchange of broadscale healthcare and consumer data. The partnership delivers privacy-protected and HIPAA-compliant activations with media platforms for pharmaceutical brands as an end-to-end, closed-loop measurement and optimization solution.

This innovative and future-proofed capability enables pharmaceutical marketers to generate and activate audiences, measure the quality of the audiences reached and optimize omnichannel net conversion lift while campaigns are in market. Through a combination of privacy-protected, HIPAA-compliant data, processes and advanced AI modeling, brands can now automate “next best actions” across patient and physician journeys to drive incremental scripts and adherence, maximizing long-term profits.

Ipsos MMA’s Unified Patient & HCP Attribution model has been validated with clients and has been shown to produce measurable improvements in revenue and profits. Ipsos MMA has also been named a leader in The Forrester Wave™ : Marketing Measurement & Optimization Solutions, Q1 2022.

“We have partnered with some of the top pharma brands, their agencies, HealthVerity and industry data partners/platforms across the media ecosystem to validate that our integrated solutions will produce better results for our clients. We believe that by working closely with them to operationalize these capabilities it will prove to provide transformational results for the industry,” said Doug Brooks, EVP at Ipsos MMA. “Ipsos MMA’s Unified Patient & HCP Attribution capability unlocks the omnichannel opportunity for pharma executives by taking advantage of synergies between DTC, HCP and sales force, enabling orchestrated planning, optimizing campaigns in-market, targeting and creating new audiences and leveraging both Patient and Physician journeys for Next Best Action through an innovative use of AI.”

“With this capability, pharma brands can integrate patient and HCP marketing journeys and enhanced data attributes to generate, activate, and prioritize high-value audiences that are linked to downstream conversions while campaigns are live. Our unique solution does not rely on third-party cookies and is not impacted by advancements in data deprecation. This approach gives brand and media planners true cross-platform and omnichannel investment optimization opportunities. In a world where data privacy is critical, we can offer marketers and their agencies a safe way to activate and measure both traditional and digital channels against intended audiences,” said Robert Cardarelli, EVP Analytics and Attribution for Ipsos MMA.

What is the benefit of this approach to Pharmaceutical Marketers?

Holistic Measurement and Campaign Management
Omnichannel impact of Patient and Physician journeys to increase patient visitation, NBRx and adherence

Multi-channel Optimization
Optimize campaigns across audiences, targeting tactics, partners, creative measures and reach & frequency – while in-flight

Sequencing
Identify which Next Best Actions need to be taken across both Patient and Physician journeys to drive maximum conversion lift and ROI

Campaign Performance Management
Ensure optimal audience quality and cost per qualified audience while meeting targeting benchmarks and downstream end actions

Interoperable Data Ecosystem
With over 150 billion de-identified transactions from more than 75 unique data sources and 330 million patients, HealthVerity provides access to the largest healthcare and consumer data ecosystem available in the market today.

HIPAA-Compliant Data Clean Rooms
Securely brings together data with a HIPAA-compliant data clean room for audience selection and media measurement for back-end analytics from HealthVerity. The complete solution enables a full closed-loop process to help target and optimize campaigns while ensuring clients get the desired outcomes.

Learn more about Ipsos MMA’s Unified Patient/HCP Attribution capability.

View the full release here: https://www.prnewswire.com/news-releases/ipsos-mma-and-healthverity-partner-to-reinvent-omnichannel-patient-and-hcp-attribution-in-the-pharma-industry-301534210.html

About Ipsos MMA

Ipsos MMA is a leading global analytics consultancy founded in 1989. The company enables its clients to achieve higher revenues and operating profits via their forward-looking, data-driven analytics, software and consulting solutions. Ipsos MMA is headquartered in New York, NY and is a part of the leading global custom market research company Ipsos, which has major offices in over 80 locations worldwide. To learn more about Ipsos MMA, visit mma.com.

About HealthVerity

Pharmaceutical manufacturers, payers and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance and Exchange, enables the discovery of RWD across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about out how HealthVerity and Ipsos MMA work together visit our Partners Page.

Request Demo or More Information

It’s time to Synchronize the Science

Complete the form to explore how synchronizing transformational technologies with the nation’s largest real-world data ecosystem can fundamentally advance the science.

HealthVerity launches MOM, the Maternal Outcomes Masterset, to advance pregnancy health research

HealthVerity launches MOM, the Maternal Outcomes Masterset, to advance pregnancy health research 150 150 Doug DeMarra

HealthVerity launches MOM, the Maternal Outcomes Masterset, to advance pregnancy health research

APRIL 26, 2022

MOM delivers the pre-eminent approach to understanding clinical attributes that best answer the industry’s most challenging maternal health questions, including recent increases in maternal mortality and morbidity in the U.S.

PHILADELPHIA, PA — (PRNewswire) — HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data, today announced the launch of MOM, the Maternal Outcomes Masterset, a groundbreaking approach for generating novel insights around the impact of healthcare interventions for pregnant women and their babies. By accurately linking de-identified healthcare records of over 1.6 million pregnant women to their newborns, HealthVerity delivers a more comprehensive way for clinical researchers to study the patient journey from pre-pregnancy to birth and beyond, all in a HIPAA-compliant and privacy protected manner.

MOM was created to address a long-standing challenge for the healthcare industry, the lack of reliable evidence on drug safety during pregnancy. The COVID-19 pandemic highlighted this gap when patients and providers were faced with minimal data and uncertain guidance on whether expectant mothers should be vaccinated. The evidence gap exists largely due to the exclusion of pregnant women from clinical trials, as well as the scarcity of relevant retrospective data sources and pregnancy registries. According to draft guidance from the U.S. Food and Drug Administration, “pregnancy registry data is not sufficient to assess the safety of products during pregnancy. Other methods are needed to corroborate registry findings.” Furthermore, with the rate of maternal mortality climbing 18% in 2020, according to a new report by the Centers for Disease Control and Prevention (CDC), the Biden-Harris Administration has recently committed to a proposed maternity care quality hospital designation.

“In the Spring of 2020, as we were building a real-world evidence system for biopharma manufacturers and regulators to assess treatment approaches for COVID-19, it became clear to us that the market had very few reliable options to study the maternal journey, ” said Sandy Leonard, Senior Vice President of Partnerships and Real-World Data for HealthVerity. “We then began a year-long process that leveraged the HealthVerity IPGE platform to uniquely solve for the complex challenges of integrating broad-based clinical data on both mother and infant while also meeting the complex privacy requirements of HIPAA.”

Adoption of MOM among the clinical research community is advancing quickly, with SK Life Sciences and the CDC among a growing list of clients leveraging the masterset to advance maternal health outcomes research.

“We were looking for a better way to capture the full maternal health journey of pregnant women using anti-seizure medication”, said Sean Stern, Director of Health Economics and Outcomes Research for SK Life Sciences. “Through MOM, we’re able to crosswalk medical claims and pharmacy data for mom and baby, allowing us to see the relationship between mom and baby and gain more visibility into pregnancy health outcomes.”

MOM is unique in its ability to accurately household de-identified healthcare records of more than 1.6 million pregnant women with their newborns by leveraging key data sources within the nation’s largest ecosystem for healthcare data. Patient cohorts can be easily designated by researchers to explore key patient interactions, health equity and many more long-term objectives.

Key attributes that only MOM can deliver:

Purpose-built for pregnancy studies
MOM was designed to enable researchers to use longitudinal clinical data to follow mothers and their babies in tandem throughout their pregnancy journey, and beyond. The mom-baby linked data preserves critical data elements such as race, ethnicity, maternal age, birth events and pregnancy outcomes to enable novel pregnancy studies.

Regulatory quality, HIPAA-compliant, and research-ready
HealthVerity has solved a complex industry challenge of linking mom and baby data in a way that maintains the most critical data elements for pregnancy-related research while also meeting the most exacting standards of HIPAA. Because MOM is covered under HealthVerity’s third party expert determination, clients can begin data analytics work on day one.

Commercial and Medicaid data for more detailed analyses
MOM is sourced from over 150 U.S. healthcare payers, including both Commercial and Medicaid payers. Currently comprised of medical claims, pharmacy claims, enrollment data and lab results from the nation’s largest real-world data ecosystem, MOM enables access to more than five years of retrospective data, as well as prospective data options leveraging HealthVerity’s persistent identity resolution technology. EMR and hospital chargemaster data will be added in the months ahead.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Contact

Jen Kaczmarczyk
Vice President of Marketing
jkaczmarczyk@healthverity.com

Request Demo or More Information

It’s time to Synchronize the Science

Complete the form to explore how synchronizing transformational technologies with the nation’s largest real-world data ecosystem can fundamentally advance the science.

The Missing Link – Solving patient privacy protection and data linkage challenges for the National Public Health Data System

The Missing Link – Solving patient privacy protection and data linkage challenges for the National Public Health Data System 150 150 Doug DeMarra

FedHealthIT

HealthVerity appoints Michael J. Cavanagh and Dr. Raquel Bono to its Board of Directors

HealthVerity appoints Michael J. Cavanagh and Dr. Raquel Bono to its Board of Directors 150 150 Doug DeMarra

HealthVerity appoints Michael J. Cavanagh and Dr. Raquel Bono to its Board of Directors

FEBRUARY 24, 2022

Cavanagh and Bono bring exceptional experience in healthcare, financial and strategic management for market-leading organizations.

PHILADELPHIA, PA — (PRNewswire) — HealthVerity, Inc., the leader in Identity, Privacy, Governance and Exchange (IPGE) for real-world data, today announced that Michael J. Cavanagh, President and Chief Financial Officer of Comcast Corporation, and Dr. Raquel Bono, Chief Health Officer of Viking, have been appointed to its board of directors.

Cavanagh brings decades of exceptional expertise in guiding high growth businesses to the HealthVerity board.  In his role at Comcast Corporation, he has a broad range of responsibilities, including overseeing all financial functions, corporate development, strategic planning, and corporate administration. Cavanagh joined Comcast in 2015 after spending more than 20 years in the financial services industry at companies like JPMorgan Chase and The Carlyle Group.

A board-certified trauma surgeon and retired Vice Admiral of the United States Navy Medical Corps, Dr. Bono most recently led Washington State’s medical and healthcare systems response to the COVID-19 pandemic.  She saw duty in Operations Desert Shield and Desert Storm and is the first female Navy medical officer to have achieved three-star rank. As CEO and Director for the Defense Health Agency (DHA), Dr. Bono led a joint, integrated combat support agency that enables all branches of the U.S. military medical services to provide health care services to combatant commands in times of both peace and war. Dr. Bono integrated an unprecedented $50 billion worldwide health care enterprise for the Army, Navy, Air Force, and Marine Corps, composed of 50 hospitals and 300 clinics that provide care to 9.5 million military personnel.

Mike Cavanagh is one of the most accomplished strategic financial leaders in corporate America and will bring strong capital markets and corporate governance expertise to the company,” said Andrew Kress, CEO of HealthVerity. “His participation on the Board will significantly enhance the value that we offer to our Pharmaceutical Manufacturer, Insurance and Government clients.”

“Dr. Bono’s decorated military service, broad organizational leadership and unique healthcare insights will be a tremendous asset to the company and we are honored to welcome her to the Board,” said Kress. “Her experience and counsel will be critical as we enter the next phase of our journey to bring critical infrastructure to the healthcare insights economy.”

Cavanagh earned a B.A. from Yale University and a J.D. from the University of Chicago. He serves on the Board of Trustees of Yale and is Chairman of its Investment Committee. Cavanagh is also a member of the Council on Foreign Relations.

Dr. Bono earned a B.A. from the University of Texas at Austin and M.D. from the School of Medicine at the Texas Tech University Health Sciences Center. She also holds an MBA from the Carson College of Business at Washington State University, is a Diplomate of the American Board of Surgery, a Fellow of the American College of Surgeons and a Senior Fellow with the Johns Hopkins University Applied Physics Laboratory. Her personal decorations include a Defense Distinguished Service Medal, three Defense Superior Service Medals, three Legion of Merit Medals, two Meritorious Service Medals, and two Navy and Marine Corps Commendation Medals.

“I am excited to be joining the HealthVerity Board at such an important moment in the company’s growth and believe that the organization is well positioned to continue to help its clients recognize the best return on investment in their data strategies,” said Cavanagh.

“I am delighted to join the HealthVerity team and look forward to contributing to the company’s technological approach to solving some of the most difficult challenges in healthcare,” said Dr. Bono.

With these appointments, Cavanagh and Bono will complement HealthVerity’s seasoned management team, an experienced board of directors and accomplished founders with extensive experience across healthcare and technology.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Contact

Jen Kaczmarczyk
Vice President of Marketing
jkaczmarczyk@healthverity.com

Request Demo or More Information

It’s time to Synchronize the Science

Complete the form to explore how synchronizing transformational technologies with the nation’s largest real-world data ecosystem can fundamentally advance the science.

13 Greater Philadelphia Startups to Watch in 2022

13 Greater Philadelphia Startups to Watch in 2022 150 150 Doug DeMarra

PHL INNO

The Future Of Blockchain In Healthcare

The Future Of Blockchain In Healthcare 150 150 Doug DeMarra

Forbes

HealthVerity broadens appeal for its IPGE Platform with key executive hires

HealthVerity broadens appeal for its IPGE Platform with key executive hires 150 150 Doug DeMarra

PR Newswire

HealthVerity awarded CDC contract for real-world data to advance COVID-19 response

HealthVerity awarded CDC contract for real-world data to advance COVID-19 response 150 150 Doug DeMarra

HealthVerity awarded CDC contract for real-world data to advance COVID-19 response

OCTOBER 07, 2021

Award covers fully interoperable, patient-centric real-world data for over 100 million US patients using privacy-preserving record linkage.

PHILADELPHIA, PA — (PRNewswire) — HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data, today announced that it has been awarded a contract with the Centers for Disease Control and Prevention (CDC) to provide a large-scale, fully interoperable, real-world dataset to advance a wide range of COVID-19 research, decision making, and public health impact objectives. Using Privacy-Preserving Record Linkage (PPRL), the HealthVerity data asset securely links de-identified patient-level data across medical and pharmacy claims, chargemaster, electronic medical records, and lab data, including genomic sequencing of COVID-19 variants, to generate comprehensive and longitudinal patient histories without sharing personally identifiable information.

The goal of this contract is to provide the CDC with a real-world dataset that is uniquely suited to provide novel insights into new and emerging priority questions related to SARS-CoV-2 variants, vaccinations, testing, re-infection, health impact, natural history, and the long-term effects of COVID-19. The data has high impact potential for CDC’s COVID-19 response and surveillance efforts because it offers CDC scientists the opportunity to conduct complex analyses and develop use cases on disease patterns, progression, and health outcomes. Leveraging its HealthVerity IPGE platform, including the nation’s largest privacy-protected healthcare and consumer data ecosystem, HealthVerity is assembling the largest, fully interoperable, real-world COVID-19 data asset ever acquired by the CDC.

“HealthVerity is proud to support the CDC in leveraging strategic data assets on its quest to understand the broad impact of COVID-19 on patients, healthcare systems, and communities,” said Andrew Kress, CEO at HealthVerity. “We are pleased that our expertise in patient identity resolution and privacy management combined with the broad cross-sectional healthcare and consumer data we manage on behalf of our data partners uniquely enables us to deliver a level of dimensionality for evidence generation that is critical to this major public health endeavor.”

In addition to COVID-19, the agreement provides the CDC with access to timely and comprehensive data on other key therapeutic areas such as viral hepatitis and HIV and the impact on key demographic groups, all in a privacy-protected, HIPAA-compliant manner.

HealthVerity has a history of serving key governmental health agencies to support public health initiatives. Most recently, HealthVerity supported the National Cancer Institute (NCI) for a groundbreaking study of SARS-CoV-2 antibodies in February 2021, announced a research contract with the U.S. Food and Drug Administration (FDA) to support COVID-19 clinical study and treatment opportunities in June 2020 and was awarded a PPRL contract for COVID-19 vaccine data with the Department of Health and Human Services (HHS) in November 2020.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Contact

Jen Kaczmarczyk
Vice President of Marketing
jkaczmarczyk@healthverity.com

Request Demo or More Information

It’s time to Synchronize the Science

Complete the form to explore how synchronizing transformational technologies with the nation’s largest real-world data ecosystem can fundamentally advance the science.